Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
872
datasets available to search
ShareScore release 0.9.0
Dataset results
872 results for “disease progression”
Finding treatment effects in Alzheimer’s trials in the face of disease progression heterogeneity
Open the record for dataset details and reuse information.
Data for: Infectious disease and sickness behaviour: tumour progression affects interaction patterns and social network structure in wild Tasmanian devils
Open the record for dataset details and reuse information.
Data from: Measurement of infection efficiency of a major wheat pathogen using time-resolved imaging of disease progress
Infection efficiency is a key epidemiological parameter that determines the proportion of pathogen spores able to infect and cause lesions once they have landed on a susceptible plant tissue. In this study, we present an improved method to measure infection efficiency of Zymoseptoria tritici using a replicated greenhouse experiment. Z. tritici is a fungal pathogen that infects wheat leaves and causes Septoria tritici blotch (STB), a major disease of wheat worldwide. We devised an original experimental setup, where we (i) attached living wheat leaves to metal plates allowing for time‐resolved imaging of disease progress in planta. Since lesions were continuously appearing, expanding and merging during the period of up to three weeks, daily measurements were necessary for accurate counting of lesions. We also (ii) used reference membranes to characterize the density and the spatial distribution of inoculated spores on leaf surfaces. In this way, we captured the relationship between the number of lesions and the number of viable spores deposited on the leaves and estimated the infection efficiency of about 4% from the slope of this relationship. Our study provides a proof of principle for an accurate and reliable measurement of infection efficiency of Z. tritici. The method opens opportunities for determining the genetic basis of the component of quantitative resistance that suppresses infection efficiency. This knowledge would improve breeding for quantitative resistance against STB, a control measure considered more durable than deployment of major resistance genes.
Presence of skin α-synuclein deposits discriminates Parkinson's disease from progressive supranuclear palsy and corticobasal syndrome
<p>Dataset </p>
Data from: Assessment of disease progression in dysferlinopathy – a one year cohort study
Objective: To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods: 193 patients with dysferlinopathy were recruited to the Jain Foundation's International Clinical Outcome Study for Dysferlinopathy. Baseline, 6 months and 1 year assessments included: adapted North Star Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6 minute walk test (6MWT), Brooke Scale, Jebsen Test, manual muscle testing (MMT) and hand-held dynamometry (HHD). Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant (mild, moderate or severe based on a-NSAA score) or non-ambulant (unable to complete a 10m walk)) and clinical diagnosis. Results: The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate group while 6MWT was most sensitive in the severe group. The 10m walk test was the only test showing significant change across all ambulant severity groups. In non-ambulant patients, the MFM domain 3, wrist flexion strength and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1 year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion: Certain functional outcome measures can detect changes over 6 months and one year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials.
Association of specific biotypes in patients with Parkinson's disease and disease progression
<p><span><b>Objective </b></span></p> <p><span>To identify biotypes in newly diagnosed Parkinson's disease patients and test whether these biotypes could explain inter-individual differences in longitudinal progression. </span></p> <p><span><b>Methods</b></span></p> <p><span>In this longitudinal analysis, we use a data-driven approach clustering PD patients from the Parkinson's Progression Markers Initiative (PPMI) (n = 314, age = 61.0 ± 9.5, 34.1% female, 5 years follow-up). Voxel-level neuroanatomical features were estimated using deformation-based morphometry (DBM) of T1-weighted MRI. Voxels whose deformation values were significantly correlated (<i>P</i> < 0.01) with clinical scores (MDS-UPDRS-Parts I-III, MDS-UPDRS-total, tremor score, and postural instability and gait difficulty score) at baseline were selected. Then, these neuroanatomical features were subjected to hierarchical cluster analysis. Changes in the longitudinal progression and neuroanatomical pattern were compared between different biotypes. </span></p> <p><span><b>Results</b></span></p> <p><span>Two neuroanatomical biotypes were identified: (i) biotype 1 (n = 114) with subcortical brain volume as smaller than heathy controls; (ii) biotype 2 (n = 200) with subcortical brain volumes larger than heathy controls. Biotype 1 had more severe motor impairment, autonomic dysfunction, and very much worse REM sleep behavior disorder than biotype 2 at baseline. Although disease duration at initial visit and follow-up were similar between biotypes, PD patients with smaller subcortical brain volume had poorer prognosis, with more rapid decline in several clinical domains and in dopamine functional neuroimaging over an average of five years. </span></p> <p><span><b>Conclusion</b></span></p> <p><span>Robust neuroanatomical biotypes exist in PD with distinct clinical and neuroanatomical pattern. These biotypes can be detected at diagnosis, and predict the course of longitudinal progression, which should benefit trial design and evaluation.</span></p>
PRospective Evaluation of Interstitial Lung DIsease Progression With Quantitative CT
ClinicalTrials.gov study NCT05609201. IPD Sharing: YES. Countries: 1. Publications: 0.
SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases
ClinicalTrials.gov study NCT03389152. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
ClinicalTrials.gov study NCT01111461. IPD Sharing: Not stated. Countries: 8. Publications: 0.
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
ClinicalTrials.gov study NCT02469701. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
ClinicalTrials.gov study NCT00256204. IPD Sharing: Not stated. Countries: 0. Publications: 4.
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
ClinicalTrials.gov study NCT07362225. IPD Sharing: NO. Countries: 1. Publications: 0.
Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients
ClinicalTrials.gov study NCT03326622. IPD Sharing: NO. Countries: 0. Publications: 33.
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
ClinicalTrials.gov study NCT04400058. IPD Sharing: Not stated. Countries: 3. Publications: 0.
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-wor
ClinicalTrials.gov study NCT04702893. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndro
ClinicalTrials.gov study NCT04729751. IPD Sharing: Not stated. Countries: 7. Publications: 0.
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.gov study NCT06675864. IPD Sharing: YES. Countries: 7. Publications: 0.
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
ClinicalTrials.gov study NCT00098865. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
ClinicalTrials.gov study NCT04664075. IPD Sharing: YES. Countries: 1. Publications: 0.
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
ClinicalTrials.gov study NCT00887458. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.